Analyst Ratings For Feedback plc (LON:FDBK)
Today, Northland Securities reiterated its Corporate rating on Feedback plc (LON:FDBK).
There are no ratings tracked in the last 12 months. on the stock.
The current consensus rating on Feedback plc (LON:FDBK) is N/A (Score: NaN) with a consensus target price of per share, a potential .
Some recent analyst ratings include
- 3/3/2017-Northland Securities Reiterated Rating of Corporate.
- 4/29/2015-Sanlam Securities Reiterated Rating of Speculative Buy.
About Feedback plc (LON:FDBK)
Feedback plc is a United Kingdom-based medical imaging software company. The Company is engaged in providing imaging tools for clinical decision makers. The Company is engaged in developing techniques and managing workflow for medical practitioners involved in research and in treating patients. The Company offers TexRAD, which is engaged in providing medical research and it can be used to manage clinical trials and helps to manage pharmaceuticals. The Company is engaged in identifying imaging biomarkers that can be used in detection of cancer. It offers Cadran, a medical imaging tools for decision support. Cadran Image Storage Management offers fully featured image display, review and manipulation options and enterprise archiving for clinical, non-clinical and teaching use. The Company’s subsidiaries include Feedback Black Box Company Limited, Feedback Data GmbH, Brickshield Limited, Cambridge Computed Imaging Limited, TexRAD Limited and Prostate Checker Ltd.
Recent Trading Activity for Feedback plc (LON:FDBK)
Shares of Feedback plc closed the previous trading session at 1.87 up +0.12 6.86% with 0 shares trading hands.